Should I buy or sell Pharvaris stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHVS shares. View PHVS analyst ratings or view top-rated stocks .

What is Pharvaris' stock price target for 2024?

4 brokerages have issued 1 year price objectives for Pharvaris' stock. Their PHVS share price targets range from $11.00 to $50.00. On average, they anticipate the company's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 69.6% from the stock's current price. View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts .

How have PHVS shares performed in 2024?

Pharvaris' stock was trading at $28.05 on January 1st, 2024. Since then, PHVS shares have decreased by 31.7% and is now trading at $19.16. View the best growth stocks for 2024 here .

Are investors shorting Pharvaris?

Pharvaris saw a drop in short interest in March. As of March 31st, there was short interest totaling 9,900 shares, a drop of 33.6% from the March 15th total of 14,900 shares. Based on an average daily trading volume, of 104,100 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the stock are sold short. View Pharvaris' Short Interest .

When is Pharvaris' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our PHVS earnings forecast .

How were Pharvaris' earnings last quarter?

Pharvaris (NASDAQ:PHVS) released its earnings results on Wednesday, November, 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.10.

When did Pharvaris IPO?

Pharvaris (PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.

How do I buy shares of Pharvaris?

Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PHVS

Pharvaris (PHVS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free PHVS Stock Alerts

$19.16

+0.74 (+4.02%)

(As of 04/19/2024 ET)

Compare

Today's Range: $18.05
▼
$20.02
50-Day Range: $18.42
▼
$28.87
52-Week Range: $7.93
▼
$33.00

Volume: 133,811 shs
Average Volume: 104,215 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $32.50

Get Pharvaris alerts:

Pharvaris MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 69.6% Upside
$32.50 Price Target
Short Interest: Healthy
0.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 12 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.20) to ($2.56) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.81 out of 5 stars

3.3

Analyst's Opinion

Consensus Rating
Pharvaris has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.
Amount of Analyst Coverage
Pharvaris has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.10% of the float of Pharvaris has been sold short.
Short Interest Ratio / Days to Cover
Pharvaris has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Pharvaris has recently decreased by 33.56%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Pharvaris does not currently pay a dividend.
Dividend Growth
Pharvaris does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PHVS.

2.0

News and Social Media Coverage

News Sentiment
Pharvaris has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 12 news articles for Pharvaris this week, compared to 2 articles on an average week.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Pharvaris insiders have not sold or bought any company stock.
Percentage Held by Insiders
11.84% of the stock of Pharvaris is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Pharvaris are expected to decrease in the coming year, from ($2.20) to ($2.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Pharvaris is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Pharvaris is -6.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Pharvaris has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Pharvaris Stock (NASDAQ:PHVS)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.

PHVS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PHVS Stock News Headlines

April 19, 2024 | americanbankingnews.com

Pharvaris Forecasted to Earn Q4 2024 Earnings of ($0.54) Per Share (NASDAQ:PHVS)

April 16, 2024 | americanbankingnews.com

Pharvaris (NASDAQ:PHVS) Price Target Cut to $34.00 by Analysts at Morgan Stanley

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 15, 2024 | markets.businessinsider.com

Pharvaris Earns Buy Rating as Deucrictibant Shows Promising Progress in HAE Treatment

April 15, 2024 | americanbankingnews.com

Pharvaris (NASDAQ:PHVS) Forecasted to Earn FY2028 Earnings of $1.43 Per Share

April 13, 2024 | americanbankingnews.com

Pharvaris (NASDAQ:PHVS) Rating Reiterated by Wedbush

April 13, 2024 | americanbankingnews.com

JMP Securities Increases Pharvaris (NASDAQ:PHVS) Price Target to $50.00

April 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Pharvaris on Strong HAE Drug Potential and Solid Financials

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | finance.yahoo.com

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

April 12, 2024 | investing.com

Pharvaris appoints new CFO to bolster financial strategy

April 11, 2024 | finanznachrichten.de

Pharvaris N.V.: Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Pharvaris on Strong Clinical Progress and Financial Stability

April 11, 2024 | seekingalpha.com

PHVS Pharvaris N.V.

April 10, 2024 | investorplace.com

PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023

April 10, 2024 | globenewswire.com

Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

April 10, 2024 | globenewswire.com

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

April 4, 2024 | globenewswire.com

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

March 18, 2024 | globenewswire.com

Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses

March 6, 2024 | globenewswire.com

Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses

March 5, 2024 | globenewswire.com

Pharvaris to Participate in the Leerink Global Biopharma Conference 2024

February 26, 2024 | markets.businessinsider.com

Pharvaris Buy Rating Affirmed on Strong Phase 2 Data and Market Positioning for HAE Treatment

February 25, 2024 | msn.com

Pharvaris N.V. (PHVS) Price Target Increased by 6.19% to 34.97

February 22, 2024 | finance.yahoo.com

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

February 22, 2024 | globenewswire.com

Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting

February 16, 2024 | finance.yahoo.com

Pharvaris Announces Extraordinary Meeting of Shareholders

February 16, 2024 | globenewswire.com

Pharvaris Announces Extraordinary Meeting of Shareholders

See More Headlines

Receive PHVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharvaris and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PHVS
CUSIP: N/A
CIK: 1830487
Web: www.pharvaris.com
Phone: 31-71-203-6410
Fax: N/A
Employees: 82
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $32.50
High Stock Price Target: $50.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +79.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-109,180,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -47.92%
Return on Assets: -44.45%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 27.25
Quick Ratio: 27.25

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.94 per share
Price / Book: 3.67

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: -3.12

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Berndt Axel Edvard Modig CPA (Age 65)
M.B.A., Co-Founder, CEO & Executive Director
Comp: $565.02k
Ms. Anna Nijdam M.Sc. (Age 43)
R.A., Head of Strategic Finance & Principal Accounting Officer

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

PHVS Stock Analysis - Frequently Asked Questions

Should I buy or sell Pharvaris stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pharvaris in the last twelve months. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" PHVS shares.
View PHVS analyst ratings or view top-rated stocks.
What is Pharvaris' stock price target for 2024?: 4 brokerages have issued 1 year price objectives for Pharvaris' stock. Their PHVS share price targets range from $11.00 to $50.00. On average, they anticipate the company's stock price to reach $32.50 in the next twelve months. This suggests a possible upside of 69.6% from the stock's current price.
View analysts price targets for PHVS or view top-rated stocks among Wall Street analysts.
How have PHVS shares performed in 2024?: Pharvaris' stock was trading at $28.05 on January 1st, 2024. Since then, PHVS shares have decreased by 31.7% and is now trading at $19.16.
View the best growth stocks for 2024 here.
Are investors shorting Pharvaris?: Pharvaris saw a drop in short interest in March. As of March 31st, there was short interest totaling 9,900 shares, a drop of 33.6% from the March 15th total of 14,900 shares. Based on an average daily trading volume, of 104,100 shares, the short-interest ratio is currently 0.1 days. Currently, 0.1% of the shares of the stock are sold short.
View Pharvaris' Short Interest.

When is Pharvaris' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our PHVS earnings forecast.
How were Pharvaris' earnings last quarter?: Pharvaris (NASDAQ:PHVS) released its earnings results on Wednesday, November, 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.10.
When did Pharvaris IPO?: Pharvaris (PHVS) raised $126 million in an initial public offering on Friday, February 5th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Morgan Stanley, BofA Securities and SVB Leerink served as the underwriters for the IPO and Oppenheimer & Co. and Kempen & Co. were co-managers.
How do I buy shares of Pharvaris?: Shares of PHVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHVS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Pharvaris (PHVS) Stock Price, News & Analysis

Pharvaris MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Company Ownership

Earnings and Valuation

About Pharvaris Stock (NASDAQ:PHVS)

PHVS Stock Price History

PHVS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Institutional Ownership

PHVS Stock Analysis - Frequently Asked Questions

Overall MarketRank^™